Amedica, Celling Biosciences partner for biologically-enhanced implants: 5 key notes

Spinal Tech

Orthopedic and spine device company Amedica is partnering with Celling Biosciences on research and development of biologically enhanced implants.

Here are five key notes:

 

1. In the initial collaboration, Celling's scientist team will produce research indicating mesenchymal stem cells can be optimized and proliferated when using silicon nitride compared with PEEK and titanium biomaterial standards.

 

2. A recent in vivo scientific study show Amedica's proprietary silicon nitride composition outperformed PEEK in attachment testing of mesenchymal stem cells. The implant is designed to plan an active role in implant integration.

 

3. After the initial testing, Celling will translate the early findings into a clinical trail in spine and orthopedic application to further define silicon nitride's clinical advantages in combination with cell-based therapies.

 

4. Amedica CEO Sonny Bal, MD, expects the research to show the favoarable cell adhesion properties of silicon nitride for rapid bone fusion and improved patient outcomes.

 

5. The intellectual property from both partners could be leveraged in future solutions for nanotechnology.

 

"As an industry, we continue to strive for innovation beyond current standards and Celling Biosciences has always focused on innovating standards of the future," said Celling CEO Kevin Bunworth. "Current trends show many evolutions of surface modifications and surface treatments around PEEK and titanium but we believe Amedica's proprietary technology is the future progression of biologically enhanced implants."

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers